Interní Med. 2003; 5(4): 199-201

Komplikace dlouhodobé léčby heparinem v těhotenství

doc. MUDr. Věra Krčová CSc1, MUDr. Martin Procházka1, prof. MUDr. Ivo Krč DrSc2, MUDr. Jana Procházková1, Mgr. Luděk Slavík Ph.D1
1 Hemato-onkologická klinika FN a LF UP v Olomouci
2 II. interní klinika FN a LF UP Olomouc

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krčová V, Procházka M, Krč I, Procházková J, Slavík L. Komplikace dlouhodobé léčby heparinem v těhotenství. Interní Med. 2003;5(4):199-201.

Uvedení dlouhodobé léčby heparinem do porodnické praxe jako profylaktické a léčebné opatření vedlo k výraznému poklesu morbidity a mortality pacientů.

Cílem vlastní studie bylo zhodnocení výskytu hlavních i vedlejších účinků, tj. osteoporózy, krvácivých projevů a trombocytopenie, vzniklých v rámci dlouhodobé terapie těmito léky.

V posledním období jsme sledovali skupinu 32 těhotných, které byly léčeny pro různé trombotické projevy nízkomolekulárním heparinem (LMWH) nejméně po dobu tří měsíců (rozpětí 90 až 270 dnů). Na základě získaných výsledků jsme mohli potvrdit bezpečnost a účinnost LMWH jak z hlediska matky, tak také plodu. Výskyt nepříznivých vedlejších účinků byl minimální. Pomocí denzitometrie, provedené v minimálním intervalu dvou měsíců od porodu, byla prokázána pouze u jedné nemocné osteoporóza a v dalším případě osteopenie.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aburahma AF, et al. Management of deep vein thrombosis of the lower extremity in pregnancy: a challenging dilemma. Am Surg 1999; 65: 164-167. Go to original source...
    2. Bokavera MI, et al. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-478. Go to original source... Go to PubMed...
    3. Dahlbäck B. Molecular genetics of venous thromboembolism. Ann Med 1995; 27: 187-192. Go to original source... Go to PubMed...
    4. Dizon-Townson DS, et al.. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997; 177: 402-405. Go to original source... Go to PubMed...
    5. Friederich PW, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125: 955-960. Go to original source... Go to PubMed...
    6. Greer IA. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med 2000; 342: 424-425. Go to original source... Go to PubMed...
    7. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-1265. Go to original source... Go to PubMed...
    8. Greer IA, et al. Thrombosis, prophylaxis in obstetrics and gynaecology. Br J Obstet Gynaecol 1993, 100: 37-40. Go to original source... Go to PubMed...
    9. Kupferminc MJ, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13. Go to original source... Go to PubMed...
    10. Lindqvist PG, et al. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73. Go to original source... Go to PubMed...
    11. Lockshin MD. Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost 1999; 82: 641-648. Go to original source... Go to PubMed...
    12. Martinelli I, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-1797. Go to original source... Go to PubMed...
    13. McColl MD, et al. Prothrombin 20210 G->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol 2000; 107: 565-569. Go to original source... Go to PubMed...
    14. Nelson-Piercy C. Low molecular weight heparin for obstetric thromboprophylaxis and gynaecology. Br J Obstet Gynaecol 1994, 101: 6-8. Go to original source... Go to PubMed...
    15. Ruiz-Irastorza G, et al. Lupus pregnancy: is heparin a risk factor for osteoporosis? Lupus 2001, 10: 597-600. Go to original source... Go to PubMed...
    16. Salomon O, et al. Risk factors associated with postpartum ovarian vein thrombosis. Thromb Haemost 1999; 82: 1015-1019. Go to original source... Go to PubMed...
    17. Sanson BJ, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-672. Go to original source... Go to PubMed...
    18. Seligsohn U, et al. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301. Go to original source... Go to PubMed...
    19. Shu H, et al. Decrease in protein C inhibitor activity and acquired APC resistance during normal pregnancy. J Thromb Thrombolysis 2000; 9: 277-281. Go to original source... Go to PubMed...
    20. Warkentin TE, et al. Heparin - induced thrombocytopenia in patients treated with low - molecular - weight - heparin or unfractionated heparin. N Engl J Med 1995, 332: 1330-1335. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.